Urology Times staff

“Oral tebipenem pivoxil hydrobromide and intravenous ertapenem had a similar safety and tolerability profile,” says Angela Talley, MD.

"Now, men have the option to seek out something minimally invasive before surgical options are breached," says Denise Asafu-Adjei, MD, MPH.

"Peyronie's disease has really seen a wide range of intralesional options through the years," says Denise Asafu-Adjei, MD, MPH.

“I think the take home message is not to take sacral neuromodulation off the table,” says Sarah Martin, DO.

“The take-home message is that there is a new form of lithotripsy,” says Jonathan D. Harper, MD.

“The social needs aren't medical conditions that can be alleviated in a doctor's office, and they shouldn't be medicalized or viewed in that way,” says Elisabeth M. Sebesta, MD.

It was previously reported that UroLift received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo).

“We are not just changing toxins for the sake of changing toxins; we are changing toxins to satisfy the needs from the clinical community,” says Min Dong, MD.

“Patients need to understand that even if you tell them that you may be doing this as an ambulatory procedure, they may actually have to stay afterwards, depending on what you find in the operating room or what happens in the postoperative period,” says Michael A. Palese, MD.

“We saw that this appears to be a safe treatment with very little bleeding,” says Jonathan D. Harper, MD.

“I think the take-home point here is that patient-centered care in the form of navigators to help support patients and provide those frequent check ins really appears to help improve adherence to therapy and progression to advanced therapies,” says Ekene Enemchukwu, MD, MPH.

"Throughout the years, I've said it's not hard to destroy tissue; it's hard to destroy tissue without destroying other things around [the cancer]," says J. Stephen Jones, MD, FACS.

"Cryotherapy was the first energy source that we were able to ablate tissues with in either the kidney or prostate and understand what that ablation would do," says J. Stephen Jones, MD, FACS.

Robert Dreicer, MD, discusses the intensification of androgen-deprivation therapy with androgen receptor pathway inhibitors in patients with metastatic castration-sensitive prostate cancer.

“Of those patients that did the test phase 82% of them actually went on to full implants,” says Sarah Martin, DO.

“We would have monthly multidisciplinary meetings to pick each other’s brains for tips we can use to get patients home more safely and quickly after surgery,” says Lee.

“The biggest improvement in my patients has been the urgency frequency and urgency incontinence,” says David W. Law, DO.

“It's very underrepresented because a lot of women just don't ask, so we're not going to know,” says Alexandra Dubinsky, MD.

“I think urology is inherently gendered,” says Polina X. Reyblat, MD.

“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.

“It's just very exciting to be a part of a company that's made such an improvement in patients' lives,” says David W. Law, DO.

“We are the only specialty that has an in-depth understanding of the pelvic floor anatomy and physiology of both genders,” says Polina X. Reyblat, MD.

“I think we need really bold and decisive acts to make the type of progress that's needed,” says Randy Vince Jr, MD.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Rachel S. Rubin, MD, discusses the evolution in the treatment of female hypoactive sexual desire disorder.

“I think the main thing is placement of the neural probe on the first go around,” says David W. Law, DO.

"We as urologists are board certified to take care of all genders. We are really good sexual medicine doctors, and we need to apply what we know about sexual medicine, not just for our male patients, but for all of our patients," says Rachel S. Rubin, MD

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

“People's concepts of immunotherapy are unfortunately quite distorted. It is not just about checkpoint inhibitors,” says Susan F. Slovin, MD, PhD.

“There are not enough male reproductive health specialists across the country at the present moment,” says Akanksha Mehta, MD, MS.

“Knowing these disparities exist, I think it's time to demand transformative changes, and not these small transactional initiatives that sometimes seem designed to shut people up,” says Randy Vince Jr, MD.